Bio B2B 〉 Selective Search Results
Your Selection Setting ：North Asia (RUS & Neighbors)；
Selective Search Results :
Pipeline & Platform 30 record(s)；
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
LT1001 is the first long-acting analgesic injection containing dinalbuphine sebacate, a prodrug of nalbuphine, in an oil-based formulation intended for sustained release of the drug. Nalbuphine is a κ-agonist / partial μ-antagonist analgesic with an analgesic effect comparable to that of morphine, yet it has a ceiling effect on respiratory depression. LT1001 was designed to take advantages
CHAP™ is a self-owned technology of SciVision Biotech Inc. which provides the unique viscoelasticity of HYADERMIS™ Facial Dermal Implant series and HYAJOINT Plus™ Synovial Fluid Supplement. CHAP™ gel with water-retention characteristic, acts as a kind of natural sponge. It creates volume in the tissue, lubricates, and transports nutrients to and from cells.
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting
Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.The patented Oradur® formulation
The PixoTest® technology utilizes the lighting and image sensing module of the smartphone (or mobile device) to detect the color change reaction on the biochemical test strip (US patent granted). The image of the test strip is captured by the front camera of the smartphone and analyzed via the measurement algorithm to turn out a quantified or semi-quantified result. With the control on light
PEP503 (A Radio-enhancer)
Radiation therapy is a common treatment modality for varies of cancers and may apply to more than 60% of cancer patients. It is often used alone or in combination with chemotherapy. However, radiation therapy also has notable disadvantages, such as a longer treatment period and unavoidable side effects. In order to treat the cancer many technologies and methods have been developed to ameliorate radiotherapy
The R&D Center has a testing center and various laboratories specializing in drug formulation, Chinese medicine, microorganisms, and cellular and molecular biochemical functions. By using precision instruments and technologies and gathering experts from different fields, the R&D Center offers a comprehensive range of services for product inspection, research and development, and improvement
TiMAX Dental Service
In order to provide the most reliable and complete medical quality and service, TiMAX will also introduce the concept of brand service and incorporate advanced technology and dental products to the public.Through the innovative concept of an open surgery center structure and the technology of dental implants system, TiMAX Dental Service also makes use of Taiwan's excellent ICT industry technology
Noninvasive prenatal screening by next generation sequencing of maternal plasma DNA
Noninvasive prenatal genetic screening is an advance in the detection of fetal chromosomal aneuploidies that analyzes cell-free fetal DNA in the blood of a pregnant woman. Circulating cffDNA can be used to assess the genetic status of the fetus noninvasively. Massively parallel sequencing (MPS), allow faster and cheaper sequencing of cell-free DNA in maternal circulation. These technologies
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
LT3001 contains a new chemical entity which is composed of a thrombolytic polypeptide and a small molecule moiety with anti-oxidation activity. In rodent disease models where LT3001 was administered outside of the “golden (3) hours” post- stroke when tPA cannot be used, it significantly reduced brain infarction, restored blood flow and improved neuronal behavior score without hemorrhage
SB04 is a conventional drug in new use to treat patients with dry AMD. SB04 has many different mechanisms to treat patients without invasive way; even patient self-applied medication. Eye drop formulation505(b)(2) regulatory pathwayFast Track Pathway for IND in Phase II/IIIPhase II/III clinical trial is ongoing in the US and Taiwan.
Rexis® is being developed as an add-on injection therapy for patients with sepsis. Several studies have demonstrated a reduction in mortality rate with the addition of Rexis® compared to the standard treatment. Rexis® will soon initiate pivotal clinical trials follow by regulatory registrations in 2016. We hope to increase the survival rate of sepsis and bring hope to patients
PHN014 (Acute ischemia stroke)
Advantages of the productPHN014 is extracted, isolated and refined with high purity from the Astragalus membranaceus (黃耆) , which has been described in the classical texts as a qi-supplementing medicine.Long-term human experience show no drug- related toxicityPHN014 meet the current trend of new drug development ,with two-way immune regulationIt's very safe and without the risk for inducing the
Applying next generation sequencing in preimplantation genetic screening
In the past, preimplantation genetic screening with fluorescent in situ hybridization (FISH) has been used to select normal or balanced embryos for transfer. However, FISH has some drawbacks including difficulties cell fixation, signal reading and only allow identification for a limited number of chromosome. In contrast, array-comparative genomic hybridization (aCGH) can detect translocation and 24
SB01 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME, API and finished product manufactured to the USFDA IND. SB01 is an injectable anti-cancer NCE with multiple anti-tumor MOATreatement of cholangiocarcinoma has FDA Orphan Drug Designation clearancePhase I results show a favorable safety profilePhase II clinical trial of SB01 has
Isoniazid without liver toxicity
1. The common Tuberculosis (TB) drug Isoniazid has the most side effect of hepatotoxicity among all drugs, which is considered to be the major barrier of TB treatment.2. Isoniazid with new formulation has no hepatotoxicity due to the special excipient.
Cancer screening by next generation sequencing
Next generation sequencing allow higher genome throughput at a reduced cost per case. World-wide efforts to catalogue mutations in multiple cancer types are underway and this is likely to lead to new discoveries that will be translated to new diagnostic, prognostic and therapeutic targets. NGS can accurately and sensitively sequence more target genes with less DNA, with reduced cost, time. Moreover
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
Prenatal diagnosis by Oligonucleotide array-comparative genomic hybridization analysis test
Oligonucleotide array-comparative genomic hybridization analysis test (CGH) is the most powerful and progressive genome technique that allows the detection of losses and gains in chromosome copy number across the entire genome without prior knowledge of specific chromosomal abnormalities. With the more specific probes which are to detect the position of a specific gene, the more subtle changes in genetic
TRIA11 is a biosimilar indicated for osteoporosis. The current global sales of the original product reaches to $1.7 billion. An injection pen is also developed to enhance the convenience of use. TRIA11 is planned to launch in EU first, and TSH Biopharm has consulted EMA for the development plan. TRIA11 is expected to move into clinical stage by the end of 2019.
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.
SB02 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME.SB02 is an oral active anti-tumor drug NCEProven with multiple anti-cancer MOAReady for IND
Newborn genetic screening for hearing impairment using real-time PCR with FRET probes
Hearing Loss, about 2 / 3 can be attributed to genetic mutations, is the most common congenital defects, so genetic testing has become a powerful tool for the clinical assessment. Around 75–80% of all cases are inherited by recessive genes, 20–25% is inherited by dominant genes, 1–2% is inherited by X-linked patterns, and less than 1% is inherited by mitochondrial inheritance. Through
Quantitative analysis of SMN1 and SMN2 genes based on DHPLC
Autosomal recessive spinal muscular atrophy (SMA) is a common, fatal neuromuscular disease caused by homozygous absence of the SMN1 gene in approximately 95% of patients. However, a highly homologous SMN2 gene exists in the same chromosome interval, centromeric to SMN1, and hampers detection of SMN1. We develop a rapid, simple, and highly reliable method for detecting the SMN1 deletion/conversion and
Preimplantation Genetic Diagnosis
Preimplantation genetic diagnosis is an advanced technology combined with In Vitro fertilization (IVF) and molecular genetics. It can be used as the diagnosis of a single gene disorder at early embryo stage prior to implantation. Perform Day 5 embryo biopsy to obtain the Trophectoderm cell at Blastocyst stage for genetic analysis to diagnose if there is mutation of a single gene disorder
Carrier screening for fragile X syndrome
Fragile X syndrome is one of the most common inherited developmental disabilities. A problem with a specific gene, FMR1 gene which is characterized by a repetitive CGG trinucleotide, causes the disease. Normally, the FMR1 gene encodes a protein called FMR1 which is needed for brain development. But once the repeat of CGG trinucleotide is too much, it will cause the loss or deficiency of the protein